{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:07:01Z","timestamp":1788804421624,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104819","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:26:55Z","timestamp":1750793215000},"page":"104819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A new era for radium-223? Optimizing treatment by balancing efficacy and toxicity through combination therapies"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3659-4800","authenticated-orcid":false,"given":"Giovanni","family":"Farinea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cozzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Buttic\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mogavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario Francesco","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Angusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104819_bib1","series-title":"Pathophysiology of Bone Metastases in Prostate Cancer","first-page":"3","volume":"3","author":"Abrahamsson","year":"2004"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104819_bib2","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1007\/s00259-021-05345-9","article-title":"EANM position paper on the role of radiobiology in nuclear medicine","volume":"48","author":"Aerts","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104819_bib3","first-page":"2104","article-title":"Prospective evaluation of bone metabolic markers as surrogate markers of response to Radium-223 therapy in metastatic castration-resistant prostate cancer","volume":"26","author":"Agarwal","year":"2020","journal-title":"Clin. Cancer Re. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PAP.0000000000000219","article-title":"Paget\u2019s \u201cseed and soil\u201d theory of cancer metastasis: an idea whose time has come","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv. Anat. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104819_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104819_bib7","first-page":"389","article-title":"Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer","volume":"46","author":"Bobinac","year":"2005","journal-title":"Croat. Med. J."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104819_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2967\/jnumed.123.266654","article-title":"The impact of baseline PSMA PET\/CT versus CT on outcomes of 223Ra therapy in metastatic castration-resistant prostate cancer patients","volume":"65","author":"Bosch","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104819_bib9","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the \u03b1-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104819_bib10","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus Cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104819_bib11","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00259-020-04796-w","article-title":"Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223","volume":"47","author":"Caffo","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ijms25010078","article-title":"Synthetic lethality by co-inhibition of androgen receptor and polyadenosine diphosphate-ribose in metastatic prostate cancer","volume":"25","author":"Calabrese","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"September","key":"10.1016\/j.critrevonc.2025.104819_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejca.2022.06.057","article-title":"Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: a single-arm Phase II trial","volume":"173","author":"Carles","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized Phase II study evaluating the addition of Pembrolizumab to Radium-223 in metastatic castration-resistant prostate cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104819_bib15","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone Health in Cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"September","key":"10.1016\/j.critrevonc.2025.104819_bib16","doi-asserted-by":"crossref","first-page":"S1259","DOI":"10.1016\/j.annonc.2024.08.2314","article-title":"LBA71 Open-label, multicentre randomised trial of Radium223-Docetaxel versus Docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON Study)","volume":"35","author":"Conteduca","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0022-5347(01)65919-6","article-title":"Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts","volume":"156","author":"Cramer","year":"1996","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104819_bib19","article-title":"A Meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising Lutetium-177 and Actinium-225 in metastatic prostate cancer","author":"Dai","year":"2024","journal-title":"Eur. Urol. Sept."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104819_bib20","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1158\/0008-5472.CAN-07-6541","article-title":"Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib21","first-page":"47","article-title":"PET-based TheraP eligibility and outcomes of VISION-eligible patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA-617: importance of 18F-FDG-avid discordant findings","volume":"66","author":"Demirci","year":"2025","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2025.104819_bib22","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2147\/DDDT.S122417","article-title":"Radium 223 dichloride for prostate cancer treatment","volume":"11","author":"Deshayes","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104819_bib23","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00259-017-3673-9","article-title":"A randomised, phase II study of repeated Rhenium-188-HEDP combined with Docetaxel and Prednisone versus Docetaxel and Prednisone alone in castration-resistant Prostate Cancer (CRPC) metastatic to bone; the Taxium II Trial","volume":"44","author":"Dodewaard-de Jong","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"September","key":"10.1016\/j.critrevonc.2025.104819_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2020.05.001","article-title":"Impact of DNA damage repair defects on response to Radium-223 and overall survival in metastatic castration-resistant prostate cancer","volume":"136","author":"Doelen","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (ENZA-p): an open-label, multicentre, randomised, Phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104819_bib26","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cells13161396","article-title":"Impact of neuroendocrine differentiation (NED) on Enzalutamide and Abiraterone efficacy in metastatic castration-resistant prostate cancer (mCRPC): a retrospective analysis","volume":"13","author":"Farinea","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of Novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"Eur. Urol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104819_bib29","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"A phase Ib study of Atezolizumab with Radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.trecan.2020.09.006","article-title":"Emerging players in prostate cancer\u2013bone niche communication","volume":"7","author":"Furesi","year":"2021","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2014.70","article-title":"Managing bone metastases and reducing skeletal related events in prostate cancer","volume":"11","author":"Gartrell","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"September","key":"10.1016\/j.critrevonc.2025.104819_bib32","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann. Oncol."},{"issue":"July","key":"10.1016\/j.critrevonc.2025.104819_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res."},{"issue":"3.","key":"10.1016\/j.critrevonc.2025.104819_bib34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11129","article-title":"Role of Endothelin-1 in osteoblastic bone metastases","volume":"97","author":"Guise","year":"2003","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104819_bib35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104819_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.clon.2007.04.009","article-title":"Molecular biology for the radiation oncologist: The 5Rs of radiobiology meet the hallmarks of cancer","volume":"19","author":"Harrington","year":"2007","journal-title":"Clin. Oncol. R. Coll. Radiol. (Gt. Br."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12885-018-5203-y","article-title":"Radium-223 in asymptomatic patients with Castration-resistant prostate cancer and bone metastases treated in an international early access program","volume":"19","author":"Heidenreich","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104819_bib38","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, Alpha-Particle-Emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib39","first-page":"252","article-title":"Targeting of Osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in Mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104819_bib40","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cncr.35221","article-title":"Safety and effectiveness of the Radium-223-Taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)","volume":"130","author":"Higano","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib41","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.clgc.2021.03.020","article-title":"Fracture risk in men with metastatic prostate cancer treated with Radium-223","volume":"19","author":"Hijab","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus Cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104819_bib43","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104819_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with Docetaxel alone or with Strontium-89, Zoledronic Acid, or both: the TRAPEZE randomized clinical trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol."},{"issue":"April","key":"10.1016\/j.critrevonc.2025.104819_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","article-title":"Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer","volume":"530","author":"Kang","year":"2022","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104819_bib47","doi-asserted-by":"crossref","first-page":"69105","DOI":"10.18632\/oncotarget.19079","article-title":"Poly-(ADP-Ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies","volume":"8","author":"Lesueur","year":"2017","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104819_bib48","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.3390\/cancers16142603","article-title":"Radium-223 treatment produces prolonged suppression of resident osteoblasts and decreased bone mineral density in trabecular bone in osteoblast reporter Mice","volume":"16","author":"Lin","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"52","key":"10.1016\/j.critrevonc.2025.104819_bib50","doi-asserted-by":"crossref","first-page":"86937","DOI":"10.18632\/oncotarget.13520","article-title":"Sublethal exposure to alpha radiation ( 223 Ra Dichloride) enhances various carcinomas sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation","volume":"7","author":"Malamas","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pros.23955","article-title":"Extreme responses to immune checkpoint blockade following bipolar androgen therapy and Enzalutamide in patients with metastatic castration resistant prostate cancer","volume":"80","author":"Markowski","year":"2020","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib52","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-20-4476","article-title":"Randomized phase II trial of Sipuleucel-T with or without Radium-223 in men with bone-metastatic castration-resistant prostate cancer","volume":"27","author":"Marshall","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104819_bib53","article-title":"A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of Olaparib + Radium-223 vs. Radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): initial efficacy and biomarker analysis","volume":"43","author":"McKay","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104819_bib54","article-title":"Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey","author":"McManus","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104819_bib56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat. Rev. Urol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104819_bib57","article-title":"A phase III trial of Docetaxel versus Docetaxel and Radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA","volume":"39","author":"Morris","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"June","key":"10.1016\/j.critrevonc.2025.104819_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.007","article-title":"Radium-223 in combination with Docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation\/randomised phase 2a trial","volume":"114","author":"Morris","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-014-0320-6","article-title":"Corticosteroids in the management of prostate cancer: a critical review","volume":"16","author":"Ndibe","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"issue":"June","key":"10.1016\/j.critrevonc.2025.104819_bib60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-10-284","article-title":"Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases","volume":"10","author":"Nieder","year":"2010","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104819_bib61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted Radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled Phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib62","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose-response, multicenter Phase II study of Radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"European Journal Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose\u2013response, multicenter Phase II study of Radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104819_bib64","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euo.2019.02.007","article-title":"Radium-223 within the evolving treatment options for metastatic castration-resistant prostate cancer: recommendations from a European expert working group","volume":"3","author":"O","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104819_bib65","first-page":"124","article-title":"The role of osteoblasts in bone metastasis","author":"Ottewell","year":"2016"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104819_bib66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A Phase I study of combination Olaparib and Radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104819_bib67","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104819_bib68","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial","volume":"73","author":"Parker","year":"2018","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104819_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter Radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100082","article-title":"A Randomized Phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) Treated with Radium-223 dichloride alone or in combination with Abiraterone Acetate\/Prednisone or Enzalutamide","volume":"6","author":"Petrylak","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib71","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with Radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-22-2526","article-title":"Phase I Study of Niraparib in combination with Radium-223 for the treatment of metastatic castrate-resistant prostate cancer","volume":"29","author":"Quinn","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104819_bib73","first-page":"574","article-title":"Safety and survival outcomes of 177Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with Prior 223Ra treatment: the RALU study","volume":"64","author":"Rahbar","year":"2023","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2025.104819_bib74","article-title":"Retreatment of metastatic castration-resistant prostate cancer patients with 223Ra therapy in daily practice","author":"Riel","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104819_bib75","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","article-title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm Phase 3b Trial","volume":"17","author":"Saad","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104819_bib76","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of Radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a Phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104819_bib77","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/annonc\/mdx331","article-title":"Re-treatment with Radium-223: first experience from an International, Open-Label, Phase I\/II study in patients with castration-resistant prostate cancer and bone metastases","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104819_bib78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pros.23180","article-title":"Chemotherapy following Radium-223 dichloride treatment in ALSYMPCA","volume":"76","author":"Sartor","year":"2016","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104819_bib79","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib80","first-page":"311","article-title":"MIRD Pamphlet No. 22 (Abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib81","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12149-024-01990-w","article-title":"Evaluating response to Radium-223 Using 68Ga-PSMA PET\/CT imaging in patients with metastatic castration-resistant prostate cancer","volume":"39","author":"Shagera","year":"2025","journal-title":"Ann. Nucl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104819_bib83","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.clgc.2020.02.015","article-title":"Open label phase II study of enzalutamide with concurrent administration of Radium 223 dichloride in patients with castration-resistant prostate cancer","volume":"18","author":"Shore","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/cancers10060182","article-title":"Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts","volume":"10","author":"Shupp","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104819_bib85","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, Phase 3 Trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104819_bib86","article-title":"Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib87","doi-asserted-by":"crossref","first-page":"107.e1","DOI":"10.1016\/j.clgc.2022.09.002","article-title":"Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with Radium-223 in routine clinical practice in Sweden","volume":"21","author":"Stattin","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104819_bib88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.annonc.2019.10.025","article-title":"A randomised phase II trial of three dosing regimens of Radium-223 in patients with bone metastatic castration-resistant prostate cancer","volume":"31","author":"Sternberg","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104819_bib89","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104819_bib90","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","article-title":"Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models","volume":"23","author":"Suominen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104819_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus Radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 Trial","author":"Tombal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"January","key":"10.1016\/j.critrevonc.2025.104819_bib92","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco","year":"2023","journal-title":"Res. Rep. Urol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104819_bib93","article-title":"Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: a systematic literature review and meta-analysis","volume":"42","author":"Turco","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104819_bib94","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-21-0685","article-title":"Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and Radium-223 in patients with De novo metastatic hormone-sensitive prostate cancer","volume":"27","author":"Turner","year":"2021","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104819_bib95","article-title":"Mature results of a Phase 2 pilot study of Radium-223 and radiotherapy in untreated hormone-na\u00efve men with oligometastatic prostate cancer to bone","volume":"42","author":"Tward","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib96","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","article-title":"Hematologic safety of Radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial","volume":"15","author":"Vogelzang","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104819_bib97","article-title":"Outcomes of Radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104819_bib98","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104819_bib99","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3390\/ijms20102587","article-title":"Prostate cancer and bone metastases: the underlying mechanisms","volume":"20","author":"Wong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104819_bib100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40880-019-0425-1","article-title":"Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Communications (London England)"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib101","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jrr\/rrx026","article-title":"Differences in responses to X-ray exposure between osteoclast and osteoblast cells","volume":"58","author":"Zhang","year":"2017","journal-title":"J. Radiat. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104819_bib102","first-page":"462","article-title":"Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: a single-arm phase 3 study","volume":"17","author":"Zhou","year":"2021","journal-title":"AsiaPac. J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:11:01Z","timestamp":1758589861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":102,"alternative-id":["S1040842825002070"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104819","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new era for radium-223? Optimizing treatment by balancing efficacy and toxicity through combination therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104819"}}